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Abstract
Purpose Cabazitaxel has not been studied in patients
with hepatic impairment (HI). This phase I study assessed
cabazitaxel safety and pharmacokinetics in patients with
HI.
Methods Patients with advanced, non-hematologic cancer,
and normal hepatic function (Cohort 1: C-1), or mild (C-2),
moderate (C-3), severe (C-4) HI received cabazitaxel starting doses of 25, 20, 10, and 10 mg/m2, respectively. Doses
were escalated in patients with HI based on Cycle 1 doselimiting toxicities (DLTs). Adverse events and the cabazitaxel pharmacokinetic profile were assessed.
Results In C-2, three patients receiving cabazitaxel 25 mg/
m2 experienced DLTs; maximum tolerated dose (MTD)
was 20 mg/m2. In C-3, two patients receiving 20 mg/m2
experienced DLTs; MTD was 15 mg/m2. C-4 was discontinued early due to DLTs. The most frequent cabazitaxelrelated, grade 3–4 toxicity was neutropenia (42%). Cabazitaxel clearance normalized to body surface area (CL/BSA)

was lower in C-1 (geometric mean [GM] 13.4 L/h/m2) than
expected (26.4 L/h/m2), but similar in C-2 (23.5 L/h/m2)
and C-3 (27.9 L/h/m2). CL/BSA in C-4 was 18.1 L/h/m2.
Compared with C-2, CL/BSA increased 19% in C-3 (GM
ratio 1.19; 90% CI 0.74–1.91), but decreased 23% in C-4
(0.77; 0.39–1.53). Cabazitaxel free fraction was unaltered.
No significant correlation was found between grade 3–4
toxicities and pharmacokinetic parameters.
Conclusions Mild–moderate HI did not cause substantial
decline in cabazitaxel clearance. Cabazitaxel dose reductions in patients with mild–moderate HI, and a contraindication in patients with severe HI, are justified based on
safety data.
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Introduction
Cabazitaxel, a second-generation semisynthetic taxane,
has demonstrated activity in the second-line treatment of
metastatic castration-resistant prostate cancer (mCRPC)
after progression on docetaxel-based treatment [1]. Cabazitaxel is approved in combination with prednisone or prednisolone for mCRPC [1–3]. Similar to the first-generation
taxanes, paclitaxel and docetaxel, cabazitaxel is primarily metabolized by the liver, mainly by cytochrome P450
CYP3A4/5 isoenzyme and, to a lesser extent, CYP2C8, and
is excreted in the bile via the feces [2, 4, 5].
Hepatic impairment may have an unpredictable impact
on the pharmacokinetics (PK) of chemotherapies metabolized by the liver, and low serum albumin levels associated
with hepatic impairment can result in an increased fraction
of free drug leading to increased toxicity [6–9]. Based on
this, clinical trials have generally excluded patients with
significant hepatic impairment. For many chemotherapy
agents, there are no specific data to guide chemotherapy
dosing in patients with hepatic impairment and current recommendations remain empiric.
As previous studies of cabazitaxel in solid tumors
excluded patients with hepatic impairment, the safety profile of cabazitaxel in this subgroup has not been established
[1, 10]. Here, we present the results of a study that examined the PK and safety profile of cabazitaxel in patients
with varying degrees of hepatic impairment.

Materials and methods
Study design
This was an open-label, dose-escalation, multicenter, phase
I study (NCT01140607) of cabazitaxel in patients with
non-hematologic cancers and varying degrees of hepatic
function. This study was designed to evaluate the maximum
tolerated dose (MTD) and safety, and assess the PK properties and relationship between PK and safety parameters,
of cabazitaxel in patients with varying degrees of hepatic
impairment. A similar design was employed in the study of
irinotecan in patients with hepatic dysfunction [11]. This
study was approved by ethics committees/review boards at
all participating institutions, and all patients provided written informed consent prior to participation. According to
the cabazitaxel dose-escalation schedule and dose-escalation decision rules defined in the protocol, which specified
different starting dose levels for each cohort and were based
on the number of dose-limiting toxicities (DLTs) observed
at the different dose levels, a total of 39–75 patients were
expected to be enrolled. This sample size would ensure
that at least six patients would be enrolled in Cohort 1, 12
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patients at MTD in Cohort 2, six patients at MTD in Cohort
3, and six patients at MTD in Cohort 4, in order to evaluate
the safety and PK profile of cabazitaxel.
Patients
Eligible patients were aged ≥18 years with a life expectancy
of >3 months, diagnosed with metastatic or locally advanced
non-hematologic cancer for which no effective curative therapy was available, had refractory or progressive disease following standard therapies, and had normal hepatic function
or chronic hepatic impairment. Patients were enrolled into
one of four cohorts based on their degree of hepatic function,
defined using National Cancer Institute (NCI) criteria [12].
Cohort 1 had normal hepatic function, defined as total bilirubin and aspartate aminotransferase (AST) ≤ institutional
upper limit of normal (ULN); Cohort 2 had mild hepatic
impairment, defined as total bilirubin >1.0 to ≤1.5 × ULN
or AST >1.5 × ULN; Cohort 3 had moderate hepatic impairment, defined as total bilirubin >1.5 to ≤3.0 × ULN; and
Cohort 4 had severe hepatic impairment, defined as total bilirubin >3.0 to 10.0 × ULN. Stable liver function or dysfunction was required. Key exclusion criteria included Eastern
Cooperative Oncology Group (ECOG) performance status
>2, prior bone marrow transplant or cabazitaxel, known brain
metastases, history of Gilbert’s syndrome or grade ≥3 hypersensitivity to taxanes, polysorbate 80 or similar compounds,
prior anticancer therapy <3 weeks before study initiation,
concurrent or planned participation in another clinical trial,
expected need for major surgery or radiation therapy during
the study, other concurrent serious illness, acute or chronic
medical illness or psychiatric condition that might affect the
trial results or the patients’ ability to participate. Patients with
significant laboratory abnormalities requiring further investigation, unresolved significant toxicity from prior therapy, or
inadequate organ function were also excluded.
Study treatment
Patients received cabazitaxel during a 1-hour intravenous
(IV) infusion on Day 1 of each 3-week cycle until unacceptable toxicity, disease progression, withdrawal of
consent, investigator decision, or study cutoff. Different
starting doses of cabazitaxel were used for each cohort
based on information from the BEX6702 study [13]. The
cabazitaxel starting dose (dose level [DL] 0) was based on
the level of hepatic function: Cohort 1 (normal function)
received 25 mg/m2, Cohort 2 (mild hepatic impairment)
received 20 mg/m2, and Cohorts 3 and 4 (moderate or
severe hepatic impairment) received 10 mg/m2. The starting dose for Cohort 4 was decided by the Study Committee
based on safety and PK findings in the first three patients
treated in Cohort 3. Doses were adjusted in Cohorts 2, 3,
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and 4 based on DLTs observed in Cycle 1. In Cohort 2,
doses were adjusted to 15 mg/m2 (DL –1) or 25 mg/m2
(DL +1), and in Cohorts 3 and 4, doses were adjusted to
15 mg/m2 (DL +1), 20 mg/m2 (DL +2), or 25 mg/m2 (DL
+3). If a Cycle 1 DLT was observed in at least two of up
to six patients at a given dose level, no further dose escalation occurred. If a Cycle 1 DLT occurred in one of the first
three patients treated at a given dose level, three additional
patients received that dose. The MTD was the highest dose
at which none of the first three patients or one of up to six
total patients experienced a Cycle 1 DLT up to the 25 mg/
m2 dose. Use of granulocyte colony-stimulating factor
(G-CSF) was not permitted during Cycle 1.
Safety assessments
Safety evaluations included vital signs, physical examinations, ECOG performance status, electrocardiograms, and
laboratory parameter tests. Adverse events (AEs) were
assessed according to the NCI Common Terminology
Criteria for AEs (CTCAE) v4.03 [14] from the time of
informed consent until ≥30 days after last cabazitaxel dose.
DLTs were defined as cabazitaxel-related clinical AEs or
laboratory abnormalities. Liver DLTs included increases
in bilirubin and/or transaminase levels to three times the
baseline value. Other DLTs included grade 3–4 non-hematologic AEs (excluding grade 3 fatigue, anorexia, fever
without infection, inadequately treated nausea, vomiting,
mucositis or stomatitis; transaminase or bilirubin elevations returning to baseline by next treatment cycle [Cohort
1]; hypersensitivity reaction in the absence of required premedication; peripheral neuropathy returning to grade 2 by
next treatment cycle) and hematologic toxicity defined as
febrile neutropenia, grade 4 neutropenia lasting more than
seven days, or grade 4 thrombocytopenia.
Pharmacokinetic assessments
Heparinized blood samples were collected from all
patients in Cycle 1, on Day 1 immediately prior to the start
of infusion, 5 min before the end of infusion, and then at
5, 15, and 30 min and 1, 2, 3, 5, 7, and 10 h after the end
of infusion. Samples were also collected on Days 2, 3, 4,
5, 8, and 10 after cabazitaxel infusion. Cabazitaxel plasma
concentrations were analyzed using a validated liquid
chromatography with tandem mass spectrometry method
(LC-MS/MS; lower limit of quantitation [LLOQ] = 1 ng/
mL). Cabazitaxel PK parameters were calculated using
non-compartmental analysis with validated software
(PKDMS Version 2.0 with WinNonlin Professional, Version 5.2.1, Pharsight). PK parameters included maximum
observed concentration (Cmax), area under the concentration versus time curve extrapolated to infinity (AUCinf),
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area under the concentration versus time curve calculated
using the trapezoidal method from time 0 to real-time tlast
(AUClast), terminal half-life (t1/2z), total body clearance
(CL), and volume of distribution at steady state (Vss). CL
and Vss were normalized to body surface area (BSA; CL/
BSA, Vss/BSA). Effect of hepatic impairment on cabazitaxel PK parameters (CL/BSA and dose-normalized exposure parameters [AUC/dose]) was evaluated using linear
mixed-effect modelling with degree of hepatic impairment as the fixed effect. Additional plasma samples were
collected 5 min before, 3 h after and 24 h after the start
of infusion to determine the cabazitaxel free fraction after
equilibrium dialysis in buffer using a validated LC-MS/
MS method with a LLOQ of 0.1 ng/mL. Cabazitaxel free
fraction was estimated using a linear mixed-effect model,
with cohort and dose level as fixed effect and time and
BSA as continuous variable and patient as random effect.

Results
Baseline patient characteristics
Of 77 patients screened, 43 were enrolled including six
patients in Cohort 1 (normal hepatic function), 18 in
Cohort 2 (mild impairment), 12 in Cohort 3 (moderate
impairment), and seven in Cohort 4 (severe impairment)
(Table 1). The remaining patients (n = 34) were considered non-eligible based on inclusion and/or exclusion
criteria. Overall, approximately half of the patients were
male, median age was 60 years (range 18–79 years), and
most patients (81%) had an ECOG performance status of
1. Patients had various primary tumors with colon and liver
the most frequent (19% each). At study entry, most patients
had metastatic disease (91%), some had locally advanced
disease (7%), and a minority had locoregional recurrence
(2%). Median time from cancer diagnosis to first cabazitaxel dose was 2.93 years (range 0.5–17.9 years), and
median time from last relapse/progression to first cabazitaxel dose was 1.08 months (range 0.2–24.2 months).
Approximately two-thirds of patients had received three or
more prior anticancer regimens.
Treatment
The cabazitaxel doses administered in each cohort were
as follows: Cohort 1 (normal hepatic function), 25 mg/m2;
Cohort 2 (mild impairment), 20 and 25 mg/m2; and Cohorts
3 (moderate impairment) and 4 (severe impairment), 10, 15,
and 20 mg/m2 (Table 1). Patients received a median of two
cycles of cabazitaxel (range 1–31 cycles) (Table 2). The
median number of cycles and relative dose intensity versus planned dose was similar across cohorts. The median
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duration of treatment was 6 weeks (range 3–107 weeks).
All patients had discontinued study treatment at study cutoff, except for one patient in Cohort 2 (20 mg/m2) who had
received 31 cycles. Primary reasons for cabazitaxel discontinuation included disease progression (65%) and toxicity/
AEs (21%) (Table 2).
Safety data
Of the 43 treated patients, 38 were evaluable for DLTs
with five excluded due to concomitant G-CSF administration during Cycle 1 in the absence of a DLT. In Cycle 1,
13 patients (34%) across all cohorts experienced a DLT
(Table 3). Hematologic and non-hematologic DLTs were
each reported in eight patients (21%) with three patients
experiencing both. No liver-related DLTs were reported. In
Cohort 2 (mild hepatic impairment), three of five patients
receiving 25 mg/m2 experienced DLTs (grade 4 febrile
neutropenia, grade 3 hypophosphatemia, and grade 4 neutropenia without fever), and the MTD was established as
20 mg/m2. In Cohort 3 (moderate impairment), the first
two patients treated at 20 mg/m2 experienced DLTs (grade
4 neutropenic sepsis, and grade 3 febrile neutropenia and
stoma site infection), and the MTD was established as
15 mg/m2. In Cohort 4 (severe impairment), the MTD
was not established because no patient treated with 10 or
15 mg/m2 experienced DLTs during Cycle 1 and treatment was discontinued early for this cohort because the
first patient treated at 20 mg/m2 experienced DLTs and
subsequently died from a combination of septic shock,
tumor lysis syndrome and acute respiratory failure in the
context of acute renal failure and disease progression.
Based on this outcome, patient accrual into Cohort 4 was
discontinued.
AEs were assessed in all patients (Table 3). The most
frequent treatment-emergent AEs (TEAEs) of any grade
(in >25% of patients overall), regardless of causality,
were fatigue (54%), neutropenia (42%), diarrhea (40%),
nausea (40%), anemia (37%), vomiting (35%), abdominal pain (28%), and peripheral edema (26%). The most
frequent TEAEs were observed in all cohorts, except
for vomiting which was not reported in Cohort 1. The
most frequent grade 3–4 TEAEs (in >3 patients overall), regardless of causality, were neutropenia (42%),
anemia (23%), febrile neutropenia (16%), abdominal
pain (14%), leukopenia (9%), and dehydration (9%). Six
patients (14%) presented with a TEAE (of any causality)
related to hepatobiliary disorders: one patient in Cohort
2 (mild hepatic impairment) and five patients in Cohort
3 (moderate impairment). Neutropenia was the most frequent grade 3–4 treatment-related TEAE (Table 3). Analysis of AEs did not reveal any trends related to hepatic
impairment.
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Pharmacokinetics
Of 43 patients, 38 were eligible for PK assessment
(Table 4). Four patients were excluded because of PK
deviations and one patient because of ineligibility for any
defined cohort in the study. In addition, two patients from
Cohort 3 receiving cabazitaxel 10 mg/m2 were excluded
from PK analysis because they displayed aberrant PK
behaviors, including a very low Cmax and a mean CL/
BSA (517 L/h/m2) that was approximately 20-fold higher
than other patients in Cohort 3 (30.5 L/h/m2 for patients
receiving cabazitaxel 15 and 20 mg/m2 collectively). The
CL/BSA estimate for patients in Cohort 1 (normal hepatic
function; 13.4 L/h/m2) was in the very low range of typical cabazitaxel clearance shown in a previous population
PK analysis (26.4 L/h/m2, coefficient of variation: 38.8%;
n = 170) [15] and other phase I studies assessing cabazitaxel PK (28.6 L/h/m2, n = 4 [13]; 27.3 L/h/m2, n = 25
[16]; 44.7 L/h/m2 n = 21 [17]). Because of this unusually low cabazitaxel clearance in Cohort 1, meaningful PK comparisons could not be made between patients
with hepatic impairment and normal hepatic function. As
a result, comparisons were made using patients with mild
hepatic impairment. Compared with Cohort 2 (mild hepatic
impairment), Cohort 3 (moderate impairment) showed a
19% increase in CL/BSA, associated with a 14% decrease
in AUClast/dose, whereas Cohort 4 (severe impairment)
showed a 23% decrease in CL/BSA, associated with a 17%
increase in AUClast/dose (Table 5; Fig. 1a). A sensitivity
analysis, which excluded patients with erratic PK profiles,
showed consistent findings to the main analysis. Compared
with Cohort 2, Cohort 3 showed a 6% decrease in CL/
BSA (ratio: 0.94; 90% CI 0.64–1.38) and Cohort 4 showed
a 39% decrease (ratio: 0.61; 90% CI 0.36–1.05). Hepatic
impairment did not affect the free fraction of cabazitaxel (5.6–6.6% across the cohorts); thus, analysis of free
drug PK led to the same conclusions as for total drug PK
(Fig. 1b).
Correlation between safety and PK parameters
No significant correlation (p < 0.05) was found between
grade 3–4 TEAEs or laboratory abnormalities in Cycle 1
and PK parameters. Study cohort (degree of hepatic function) was not a statistically significant covariate in any of
the logistic regression models of PK parameters.
Efficacy
There were no efficacy endpoints in this study, and therefore, data were not routinely collected. However, one
patient with cholangiocarcinoma had stable disease, which
was maintained at Cycle 32.

0

0

9 (75.0)

5 (83.3)
Grade 3–4
treatmentrelated TEAE,
n (%)

2 (33.3)

1 (16.7)

0

0

0

0

Leukopenia

Fatigue

Lymphopenia

Diarrhea

Dehydration

Urinary tract
infection

Platelet count
decreased

0

0

Anemia

White blood
cell count
decreased

1 (16.7)

Febrile neutropenia

1 (8.3)

2 (16.7)

0

1 (8.3)

1 (8.3)

1 (8.3)

0

2 (16.7)

2 (16.7)

3 (25.0)
3 (25.0)

5 (83.3)

1 (16.7)

Neutropenia

Grade 3–4 treatment-related
TEAEs
occurring in
>1 patient,
n (%)

11 (91.7)

6 (100)

Liver

Grade 3–4
TEAE, n (%)

3 (27.3)
2 (18.2)

2 (50.0)

1 (25.0)

3 (27.3)

Non-hematologic

3 (75.0)

n = 11

0

0

0

0

0

1 (16.7)

0

0

0

1 (16.7)

4 (66.7)

6 (100)

6 (100)

0

1 (20.0)

2 (40.0)

3 (60.0)

n=5

0

0

0

0

0

0

0

0

0

0

1 (33.3)

1 (33.3)

3 (100)

0

0

0

0

n=3

0

0

0

0

0

0

0

2 (28.6)

0

1 (14.3)

4 (57.1)

6 (85.7)

6 (85.7)

0

1 (16.7)

0

1 (16.7)

n=6

15 mg/m2
(MTD) n = 7

10 mg/m2
n=3

20 mg/m2
(MTD) n = 12

25 mg/m2
n=6

Cohort 3
moderate hepatic impairment

Cohort 2
mild hepatic impairment

Hematologic

DLT during
Cycle 1,
n (%)

n=4

Cohort 1
25 mg/m2
normal hepatic
function
n=6

Table 3  Dose-limiting toxicities and treatment-emergent adverse events

1 (50.0)

0

0

0

0

0

1 (50.0)

0

0

1 (50.0)

0

2 (100)

2 (100)

0

2 (100)

1 (50.0)

2 (100)

n=2

20 mg/m2
n=2

0

0

0

0

0

0

0

0

0

0

0

1 (33.3)

3 (100)

0

0

0

0

n=3

10 mg/m2
n=3

0

0

1 (33.3)

0

1 (33.3)

0

0

0

1 (33.3)

0

1 (33.3)

1 (33.3)

2 (66.7)

0

0

0

0

n=3

15 mg/m2
n=3

Cohort 4
severe hepatic impairment

0

0

1 (100)

1 (100)

0

0

0

0

1 (100)

0

0

1 (100)

1 (100)

0

1 (100)

0

1 (100)

n=1

20 mg/m2
n=1

2 (4.7)

2 (4.7)

2 (4.7)

2 (4.7)

2 (4.7)

3 (7.0)

3 (7.0)

4 (9.3)

5 (11.6)

7 (16.3)

18 (41.9)

32 (74.4)

40 (93.0)

0

8 (21.1)

8 (21.1)

13 (34.2)

N = 38a

All patients
N = 43
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13
0
0

0

0

Cholangitis

Hyperbilirubinemia

0

0

0

1 (16.7)

1 (16.7)

1 (16.7)

0

0

1 (33.3)

0

1 (33.3)

1 (33.3)

1 (14.3)

1 (14.3)

1 (14.3)

1 (14.3)

4 (57.1)

3 (42.9)

a

0

0

0

0

0

0

20 mg/m2
n=2

0

0

0

0

0

0

10 mg/m2
n=3

0

0

0

0

0

0

15 mg/m2
n=3

Cohort 4
severe hepatic impairment

0

0

0

0

0

1 (100)

20 mg/m2
n=1

1 (2.3)

1 (2.3)

2 (4.7)

2 (4.7)

6 (14.0)

9 (20.9)

All patients
N = 43

DLT-evaluable population (N = 38): five patients excluded due to the administration of granulocyte colony-stimulating factor during the first three weeks of treatment in the absence of a DLT

DLT dose-limiting toxicity; MTD maximum tolerated dose; TEAE treatment-emergent adverse event

0

0

Jaundice

0

0

0

0

2 (16.7)

15 mg/m2
(MTD) n = 7

10 mg/m2
n=3

20 mg/m2
(MTD) n = 12

25 mg/m2
n=6

Cohort 3
moderate hepatic impairment

Cohort 2
mild hepatic impairment

Hepatic
failure

Any grade,
any causality
hepatobil i
aryTEAE,
n (%)

Any grade,
1 (16.7)
any causality
TEAE leading
to discontinuation, n (%)

Cohort 1
25 mg/m2
normal hepatic
function
n=6
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2220 ± 2450
(1410) [110]

15.9 ± 9.70
(13.4) [61]

1250 ± 1300
(820) [104]

CL/BSA, L/h/m2

Vss/BSA, L/m2
2770 ± 1440
(2080) [52]

30.2 ± 20.1
(24.0) [67]

4940 ± 2440
(3820) [49]

1110 ± 1090
(829) [98]
55.0 ± 38.5
(44.0) [70]

294 ± 253
(213) [86]

2310 ± 924
(2120) [40]b

26.6 ± 13.8
(22.7) [52]b

4040 ± 1630
(3740) [40]b

1420 ± 1300
(1110) [92]b
46.9 ± 25.4
(40.0) [54]b

94.7 ± 12.0
(94.1) [13]

1040 ± 1050
(787) [100]

328 ± 189
(287) [57]

25 mg/m2
n=6

1130 ± NC
(1110) [NC]

517 ± NC
(143) [NC]

2580 ± NC
(2440) [NC]

970 ± NC
(314) [NC]

206 ± NC
(62.8) [NC]

3.47 ± NC
(2.27) [NC]

184 ± NC
(54.0) [NC]

16.4 ± NC
(15.4) [NC]

10 mg/m2
n = 2a

2380 ± 1130
(2120) [47]c

33.3 ± 16.1
(30.1) [48]c

4800 ± 3160
(3950) [66]c

62.5 ± 33.0
(56.1) [53]c

526 ± 243
(478) [46]c

98.4 ± 62.3
(78.6) [63]

387 ± 154
(360) [40]

212 ± 275
(131) [130]

15 mg/m2
(MTD) n = 7

Cohort 3
moderate hepatic impairment

2610 ± NC
(2460) [NC]

22.1 ± NC
(22.0) [NC]

4660 ± NC
(4410) [NC]

39.6 ± NC
(39.4) [NC]

931 ± NC
(925) [NC]

111 ± NC
(110) [NC]

684 ± NC
(674) [NC]

333 ± NC
(294) [NC]

20 mg/m2
n=2

NC ± NC
(NC) [NC]d

NC ± NC
(NC) [NC]d

NC ± NC
(NC) [NC]d

NC ± NC
(NC) [NC]d

NC ± NC
(NC) [NC]d

76.3 ± NC
(76.2) [NC]

998 ± NC
(542) [NC]

378 ± NC
(207) [NC]

10 mg/m2
n=2

2860 ± NC
(2180) [NC]e

17.7 ± NC
(16.5) [NC]e

5330 ± NC
(4170) [NC]e

33.4 ± NC
(31.7) [NC]e

974 ± NC
(909) [NC]e

111 ± 5.23
(111) [5]

585 ± 507
(454) [87]

117 ± 93.9
(92.7) [81]

15 mg/m2
n=3

Cohort 4
severe hepatic impairment

4250 ± NC
(4250) [NC]

21.6 ± NC
(21.6) [NC]

7230 ± NC
(7230) [NC]

36.7 ± NC
(36.7) [NC]

915 ± NC
(915) [NC]

141 ± NC
(141) [NC]

591 ± NC
(591) [NC]

77.4 ± NC
(77.4) [NC]

20 mg/m2
n=1

n = 5, parameter not calculable for one patient (AUCExt >40%)

n = 0, parameter not calculable for two patients (AUCExt >40%)

d

e

n = 2, parameter not calculable for one patient (AUCExt >40%)

n = 6, parameter not calculable for one patient (AUCExt >40%)

b

c

Patients in Cohort 3 receiving cabazitaxel 10 mg/m2 and displaying aberrant PK behaviors (very low Cmax) were excluded from the statistical analysis

a

AUCinf area under the plasma concentration–time curve extrapolated to infinity; AUCEXT extrapolated area under the plasma concentration–time curve; AUClast area under the plasma concentration–time curve from time zero to the time of the last cabazitaxel concentration; CL clearance; CL/BSA clearance normalized to body surface area; Cmax maximum observed plasma concentration; CV coefficient of variation; NC not calculated; SD standard deviation; t1/2z apparent terminal half-life; Vss volume of distribution at steady state; Vss /BSA volume of distribution at steady
state normalized to body surface area

CL, L/h

Vss, L

77.9 ± 36.9
(69.7) [47]

2220 ± 1410
(1860) [63]
27.6 ± 16.7
(23.1) [60]

90.4 ± 38.8
(81.0) [43]

2010 ± 1420
(1610) [70]

AUClast,
ng*h/mL
t1/2z, h

AUCinf, ng*h/mL

893 ± 1000
(612) [112]

691 ± 563
(545) [82]

Cmax, ng/mL

20 mg/m2
(MTD) n = 9

Cohort 2
mild hepatic impairment

Cohort 1
25 mg/m2 normal
hepatic function
n=6

Parameter:
mean ± SD
(geometric mean)
[CV%]

Table 4  Pharmacokinetic parameters: descriptive statistics
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Table 5  Pharmacokinetic parameters: effect of hepatic impairment
Parameter

Cohort (hepatic function/
impairment)

CL, L/h

Cohort 1 (normal)
Cohort 2 (mild)a

CL/BSA, L/h/m2

AUCinf/dose,
ng*h/mL/mg/m2

AUClast/dose,
ng*h/mL/mg/m2

Cmax/dose,
ng/mL/mg/m2

t1/2z, h

Vss, L

Vss/BSA, L/m2

Cohort 3 (moderate)b
Cohort 4 (severe)c
Cohort 1 (normal)
Cohort 2 (mild)a
Cohort 3 (moderate)b
Cohort 4 (severe)c
Cohort 1 (normal)
Cohort 2 (mild)a
Cohort 3 (moderate)b
Cohort 4 (severe)c
Cohort 1 (normal)
Cohort 2 (mild)
Cohort 3 (moderate)d
Cohort 4 (severe)
Cohort 1 (normal)
Cohort 2 (mild)
Cohort 3 (moderate)d
Cohort 4 (severe)
Cohort 1 (normal)
Cohort 2 (mild)
Cohort 3 (moderate)d
Cohort 4 (severe)
Cohort 1 (normal)
Cohort 2 (mild)a
Cohort 3 (moderate)b
Cohort 4 (severe)c
Cohort 1 (normal)
Cohort 2 (mild)a
Cohort 3 (moderate)b
Cohort 4 (severe)c

Geometric mean
(90% CI)

n

6
14
8
3
6
14
8
3
6
14
8
3
6
15
9
6
6
15
9
6
6
15
9
6
6
14
8
3
6
14
8
3

Versus cohort 1 (normal
hepatic function)
Ratio (90% CI)

Versus cohort 2 (mild
hepatic impairment)
Ratio (90% CI)

23.00 (14.73, 35.92)

1.00

–

42.54 (31.92, 56.71)
51.50 (35.12, 75.53)
33.32 (17.91, 62.01)
13.42 (8.64, 20.83)
23.51 (17.63, 31.35)
27.86 (19.03, 40.77)
18.13 (9.73, 33.76)
74.52 (48.01, 115.68)
42.53 (31.89, 56.72)
35.91 (24.53, 52.55)
55.17 (29.62, 102.75)
64.21 (38.39, 107.40)
31.09 (22.46, 43.05)
26.6 (17.48, 40.48)
36.24 (21.67, 60.62)
21.78 (12.11, 39.18)
11.01 (7.60, 15.97)
10.08 (6.24, 16.28)
8.46 (4.71, 15.23)
71.07 (49.36, 102.31)
85.92 (68.55, 107.69)
83.64 (62.30, 112.29)
102.12 (71.46, 145.92)
1442.95 (802.87, 2593.34)
3785.17 (2593.95, 5523.44)
4005.9 (2421.05, 6628.21)
4981.61 (2201.05, 11,274.82)
819.68 (464.42, 1446.71)
2093.46 (1443.24, 3036.63)
2201.19 (1345.79, 3600.29)

1.85 (1.09, 3.14)
2.24 (1.24, 4.05)
1.45 (0.67, 3.12)
1.00
1.75 (1.04, 2.96)
2.08 (1.16, 3.72)
1.35 (0.63, 2.89)
1.00
0.57 (0.34, 0.97)
0.48 (0.27, 0.86)
0.74 (0.35, 1.59)
1.00
0.48 (0.26, 0.89)
0.41 (0.21, 0.80)
0.56 (0.27, 1.17)
1.00
0.51 (0.25, 1.01)
0.46 (0.22, 0.99)
0.39 (0.17, 0.89)
1.00
1.21 (0.79, 1.86)
1.18 (0.73, 1.89)
1.44 (0.86, 2.39)
1.00
2.62 (1.31, 5.27)
2.78 (1.27, 6.06)
3.45 (1.26, 9.46)
1.00
2.55 (1.30, 5.04)
2.69 (1.27, 5.69)

–
1.21 (0.75, 1.95)
0.78 (0.40, 1.55)
–
–
1.19 (0.74, 1.91)
0.77 (0.39, 1.53)
–
–
0.84 (0.52, 1.36)
1.30 (0.65, 2.57)
–
–
0.86 (0.50, 1.46)
1.17 (0.63, 2.14)
–
–
0.92 (0.50, 1.68)
0.77 (0.38, 1.54)
–
–
0.97 (0.67, 1.41)
1.19 (0.78, 1.81)
–
–
1.06 (0.56, 1.99)
1.32 (0.54, 3.24)
–
–
1.05 (0.57, 1.95)

2729.48 (1222.20, 6095.62)

3.33 (1.24, 8.91)

1.30 (0.54, 3.16)

AUCinf/dose, area under the plasma concentration–time curve extrapolated to infinity normalized to dose; AUCEXT, extrapolated area under the
plasma concentration–time curve; AUClast/dose, area under the plasma concentration–time curve from time zero to the time of the last cabazitaxel concentration, normalized to dose; CL, clearance; CL/BSA, clearance normalized to body surface area; CI, confidence interval; Cmax/dose,
maximum observed plasma concentration normalized to dose; t1/2z, apparent terminal half-life; Vss, volume of distribution at steady state; Vss/
BSA, volume of distribution at steady state normalized to body surface area
a
b

n = 14, parameter not calculable for one patient (AUCExt >40%)

n = 8, patients receiving cabazitaxel 10 mg/m2 and displaying aberrant PK behaviors (very low Cmax) were excluded from the statistical analysis and parameter not calculable for one patient (AUCExt > 40%)
c
d

n = 3, parameter not calculable for three patients (AUCExt > 40%)

n = 9, patients receiving cabazitaxel 10 mg/m2 and displaying aberrant PK behaviors (very low Cmax) were excluded from the statistical analysis

Discussion
This study assessed the safety and PK of cabazitaxel in
patients with hepatic impairment compared with patients
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who have normal hepatic function. Cabazitaxel is primarily metabolized by the liver, and therefore, it is important
to assess the effect of hepatic impairment on cabazitaxel
metabolism. The first-generation taxanes, docetaxel and
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a
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Cabazitaxel clearance normalized to body surface area (CL/BSA) Cabazitaxel clearance normalized to body surface area (CL/BSA)
Individual and mean (and standard deviation) per cohort
Mean (and standard deviation) per dose and per cohort
25 mg/m2 - Normal (n = 6), Mild (n = 5)

15 mg/m2 - Moderate (n = 6), Severe (n = 2)

20 mg/m2 - Mild (n = 9), Moderate (n = 2), Severe (n = 1)

80
60
CL/BSA, L/h/m2

CL/BSA, L/h/m2

60

40

20

0

1
Normal

2
Mild

3
Moderate

40

20

0

4
Severe

1
Normal

2
Mild

Cohort

b

Cabazitaxel free fraction, %

12

3
Moderate

4
Severe

Cohort
Cabazitaxel free fraction
Mean (and standard deviation) per cohort
Normal (n = 6)
Mild (n = 15)
Moderate (n = 9)
Severe (n = 6)

10

8

6

4
0.92

3
Time, hours

24

Fig. 1  Pharmacokinetic analysis in the pharmacokinetic population (erratic profiles excluded) of a CL/BSA b cabazitaxel free fraction

paclitaxel, are administered at lower doses in patients with
hepatic impairment because of an increased risk of myelosuppression, stomatitis, neutropenia, and treatment-related
death [4, 5, 18, 19].
In this study, parameters used for patient recruitment
and for defining hepatic impairment levels were based on
the NCI criteria [12] and were previously used in a study
assessing irinotecan in patients with hepatic dysfunction
[11]. These parameters made patient recruitment challenging, particularly for severely impaired patients. Using albumin levels or Child-Pugh-Turcotte classification scores,
versus metabolic status, to define hepatic function and
guide cohort allocation may have been beneficial and may
have provided a more accurate characterization of hepatic

function. Potentially, albumin levels could have been correlated with PK and safety parameters.
The MTD of cabazitaxel administered by IV infusion
every 3 weeks in patients with advanced solid tumors was
determined to be 20 and 15 mg/m2 for patients with mild
or moderate hepatic impairment, respectively. For patients
with severe hepatic impairment, treatment in Cohort 4 was
prematurely discontinued following the death of the first
patient treated with cabazitaxel 20 mg/m2 from a combination of AEs (including DLTs) and disease progression; therefore, the MTD in this cohort of patients remains
undetermined.
The overall safety profile of cabazitaxel was consistent with the known safety profile with no new safety issues
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identified. The safety profile of cabazitaxel 20 and 15 mg/
m2 (MTD) in patients with mild or moderate hepatic impairment, respectively, was generally similar to that observed in
patients with normal hepatic function receiving 25 mg/m2. In
this study, prophylactic use of G-CSF was not permitted during Cycle 1. Prophylactic administration of G-CSF has the
ability to reduce hematologic toxicity in clinical practice.
As CL/BSA for cabazitaxel in patients with normal
hepatic function was low compared with historical data
[13, 15–17], PK data for patients with normal hepatic
function in this study could not be used in comparisons.
The reason for these low values is unclear; patients with
no reason for exclusion showed variability in parameters
and erratic PK profiles. The number of patients with normal hepatic function was small (n = 6), which may help
explain the large variability in cabazitaxel clearance for this
cohort as several outliers considerably affected the average values of the cohort and created a substantial shift in
average CL/BSA. Patients with mild or moderate hepatic
impairment had CL/BSA values comparable to historical
data, suggesting no influence of mild or moderate hepatic
impairment on cabazitaxel PK. There was no evidence
that moderate versus mild hepatic impairment resulted in
a substantial decline in cabazitaxel clearance. There was
no evidence that the lower MTD in patients with mild or
moderate hepatic impairment, compared with the approved
25 mg/m2 cabazitaxel dose, were due to higher cabazitaxel
exposure. Patients with severe hepatic impairment had a
numerically decreased CL/BSA compared with mildly
impaired patients, indicating some effect of severe impairment on PK parameters. This numerical increase in cabazitaxel exposure may, in part, explain the increased toxicity
of cabazitaxel observed in this patient cohort. However,
because of the limitations of a small study and unbalanced
sample sizes per cohort, this observation should be interpreted with caution.
Hepatic impairment had no effect on the cabazitaxel
unbound fraction with a low free fraction estimated across
all cohorts (5.6–6.6%). These results are consistent with
the high binding of cabazitaxel to total plasma proteins
observed ex vivo and in vitro (89–92%) [2, 15, 17].
Even though cabazitaxel is primarily metabolized by
CYP3A in the liver, the minimal impact of hepatic impairment on cabazitaxel PK parameters is consistent with a high
cabazitaxel clearance driven by hepatic blood flow and is
also consistent with the modest effect that repeated ketoconazole (a strong CYP3A inhibitor) administration has
on cabazitaxel clearance; in one study, repeated ketoconazole administration resulted in a 20% decrease in cabazitaxel clearance [20]. Data from this study support the use
of cabazitaxel in patients with mild or moderate hepatic
impairment at reduced doses of 20 and 15 mg/m2, respectively, compared with the approved dose of 25 mg/m2.
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Based on this study and in the absence of appropriate data,
the use of cabazitaxel is not recommended in patients with
severe hepatic impairment. Based on PK data, there was no
evidence of a relationship between safety and PK parameters as the lower MTDs could not be justified by higher
cabazitaxel exposure in patients with mild or moderate
hepatic impairment. However, dose reductions of cabazitaxel in patients with mild or moderate hepatic impairment,
and contraindication in patients with severe hepatic impairment, are justified based on safety data. A recent phase III
non-inferiority study (PROSELICA) has demonstrated
that cabazitaxel administered at a dose of 20 mg/m2 maintains at least 50% of the survival benefit observed with the
approved 25 mg/m2 dose of cabazitaxel versus mitoxantrone
in the previous phase III TROPIC study [1], in patients with
mCRPC who have received prior docetaxel treatment [21].
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